Dihydroartemisinin and transferrin dual-dressed nano-graphene oxide for a pH-triggered chemotherapy

Biomaterials

Volumn 62, Issue , 2015, Pages 35-46

  Liu, Lijuan ^a   Wei, Yanchun ^a   Zhai, Shaodong ^a   Chen, Qun ^a   Xing, Da ^a,b  

^a SOUTH CHINA NORMAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Chemotherapy; Dihydroartemisinin; Graphene oxide; Reactive oxygen species; Transferrin

Indexed keywords

CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; GRAPHENE; GRAPHENE OXIDE; IONS; MAMMALS; MOLECULAR BIOLOGY; REACTIVE OXYGEN SPECIES; TARGETED DRUG DELIVERY; TUMORS;

ARTEMISIA ANNUA; CANCER THERAPY; DIHYDROARTEMISININ; FERROUS ION; SIDE EFFECT; TRANSFERRIN; TRANSFERRIN RECEPTORS; YIELDING MECHANISMS;

IRON COMPOUNDS;

ANTINEOPLASTIC AGENT; DIHYDROARTEMISININ; DIHYDROARTEMISININ GRAPHENE OXIDE TRANSFERRIN; FERRIC ION; FERROUS ION; GRAPHENE OXIDE; REACTIVE OXYGEN METABOLITE; TRANSFERRIN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; ARTEMISININ DERIVATIVE; DELAYED RELEASE FORMULATION; GRAPHITE; NANOCAPSULE; OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SPECIFICITY; DRUG SYNTHESIS; DRUG UPTAKE; ENDOCYTOSIS; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LYSOSOME; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; TARGET CELL; TUMOR CELL; TUMOR VOLUME; ADMINISTRATION AND DOSAGE; ANIMAL; BAGG ALBINO MOUSE; CELL SURVIVAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DIFFUSION; DRUG EFFECTS; NEOPLASMS, EXPERIMENTAL; PARTICLE SIZE; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE; ULTRASTRUCTURE;

ARTEMISIA ANNUA; MUS;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARTEMISININS; CELL LINE, TUMOR; CELL SURVIVAL; DELAYED-ACTION PREPARATIONS; DIFFUSION; FEMALE; GRAPHITE; HYDROGEN-ION CONCENTRATION; MICE; MICE, INBRED BALB C; NANOCAPSULES; NEOPLASMS, EXPERIMENTAL; OXIDES; PARTICLE SIZE; TRANSFERRIN; TREATMENT OUTCOME;

EID: 84930813482     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.05.036     Document Type: Article

References (46)

1. Efferth T., Benakis A., Romero M.R., Tomicic M., Rauh R., Steinbach D., Hafer R., Stamminger T., Oesch F., Kaina B., Marschall M. Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic. Biol. Med. 2004, 37:998-1009.
2. Krishna S., Bustamante L., Haynes R.K., Staines H.M. Artemisinins: their growing importance in medicine. Trends Pharmacol. Sci. 2008, 29:520-527.
3. O'Neill P.M., Barton V.E., Ward S.A. The molecular mechanism of action of artemisinin-the debate continues. Molecules 2010, 15:1705-1721.
4. Beekman A.C., Wierenga P.K., Woerdenbag H.J., Van Uden W., Pras N., Konings A.W., el-Feraly F.S., Galal A.M., Wikstrom H.V. Artemisinin-derived sesquiterpene lactones as potential antitumour compounds: cytotoxic action against bone marrow and tumour cells. Planta Med. 1998, 64:615-619.
5. Posner G.H., Oh C.H., Wang D., Gerena L., Milhous W.K., Meshnick S.R., Asawamahasadka W. Mechanism-based design, synthesis, and in vitro antimalarial testing of new 4-methylated trioxanes structurally related to artemisinin: the importance of a carbon-centered radical for antimalarial activity. J. Med. Chem. 1994, 37:1256-1258.
6. Jefford C.W., Vicente M.G.H., Jacquier Y., Favarger F., Mareda J., Millasson-Schmidt P., Brunner C., Burger U. The deoxygenation and isomerization of artemisinin and artemether and their relevance to antimalarial action. Chim. Acta. 1996, 79:1475-1487.
7. 2+-mediated decomposition, PfATP6 binding, and antimalarial activities of artemisone and other artemisinins: the unlikelihood of C-centered radicals as bioactive intermediates. ChemMedChem. 2007, 2:1480-1497.
8. Woerdenbag H.J., Moskal T.A., Pras N., Malingre T.M., el-Feraly F.S., Kampinga H.H., Konings A.W. Cytotoxicity of artemisinin-related endoperoxides to Ehrlich ascites tumor cells. J. Nat. Prod. 1993, 56:849-856.
9. Efferth T. Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells. Curr. Drug Targets 2006, 7:407-421.
10. Mercer A.E., Maggs J.L., Sun X.M., Cohen G.M., Chadwick J., O'Neill P.M., Park B.K. Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds. J. Biol. Chem. 2007, 282:9372-9382.
11. Rouault T.A. The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat. Chem. Biol. 2006, 2:406-414.
12. Heath J.L., Weiss J.M., Lavau C.P., Wechsler D.S. Iron deprivation in cancer-potential therapeutic implications. Nutrients 2013, 5:2836-2859.
13. Kemp J.D. Iron deprivation and cancer: a view beginning with studies of monoclonal antibodies against the transferrin receptor. Histol. Histopathol. 1997, 12:291-296.
14. Qin X.C., Guo Z.Y., Liu Z.M., Zhang W., Wan M.M., Yang B.W. Folic acid-conjugated graphene oxide for cancer targeted chemo-photothermal therapy. J. Photochem Photobiol. B 2013, 120:156-162.
15. Yang H.W., Lu Y.J., Lin K.J., Hsu S.C., Huang C.Y., She S.H., Liu H.L., Lin C.W., Xiao M.C., Wey S.P., Chen P.Y., Yen T.C., Wei K.C., Ma C.C. EGRF conjugated PEGylated nanographene oxide for targeted chemotherapy and photothermal therapy. Biomaterials 2013, 34:7204-7214.
16. Lantz E., Cunningham I., Higa G.M. Targeting HER2 in breast cancer: overview of long-term experience. Int. J. Womens Health 2010, 1:155-171.
17. Xu Q., Liu Y., Su S., Li W., Chen C., Wu Y. Anti-tumor activity of paclitaxel through dual-targeting carrier of cyclic RGD and transferrin conjugated hyperbranched copolymer nanoparticles. Biomaterials 2012, 33:1627-1639.
18. Hong H., Yang K., Zhang Y., Engle J.W., Feng L., Yang Y., Nayak T.R., Goel S., Bean J., Theuer C.P., Barnhart T.E., Liu Z., Cai W. In vivo targeting and imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographene. ACS Nano 2012, 6:2361-2370.
19. Guo Y., Wang L., Lv P., Zhang P. Transferrin-conjugated doxorubicin-loaded lipid-coated nanoparticles for the targeting and therapy of lung cancer. Oncol. Lett. 2015, 9:1065-1072.
20. Du W., Fan Y., Zheng N., He B., Yuan L., Zhang H., Wang X., Wang J., Zhang X., Zhang Q. Transferrin receptor specific nanocarriers conjugated with functional 7peptide for oral drug delivery. Biomaterials 2013, 34:794-806.
21. Liu G., Shen H., Mao J., Zhang L., Jiang Z., Sun T., Lan Q., Zhang Z. Transferrin modified graphene oxide for glioma-targeted drug delivery: in vitro and in vivo evaluations. ACS Appl. Mater. Interfaces 2013, 5:6909-6914.
22. Cui Y., Xu Q., Chow P.K., Wang D., Wang C.H. Transferrin-conjugated magnetic silica PLGA nanoparticles loaded with doxorubicin and paclitaxel for brain glioma treatment. Biomaterials 2013, 34:8511-8520.
23. Liu Z., Fan A.C., Rakhra K., Sherlock S., Goodwin A., Chen X., Yang Q., Felsher D.W., Dai H. Supramolecular stacking of doxorubicin on carbon nanotubes for in vivo cancer therapy. Angew. Chem. Int. Ed. Engl. 2009, 48:7668-7672.
24. Moreira A.F., Gaspar V.M., Costa E.C., Melo-Diogo D.D., Machado P., Paquete C.M., Correia I.J. Preparation of end-capped pH-sensitive mesoporous silica nanocarriers for on-demand drug delivery. Eur. J. Pharm. Biopharm. 2014, 88:1012-1025.
25. Liu G.X., Fang G.Q., Xu W. Dual targeting biomimetic liposomes for Paclitaxel/DNA combination cancer treatment. Int. J. Mol. Sci. 2014, 15:15287-15303.
26. Zhang W., Guo Z., Huang D., Liu Z., Guo X., Zhong H. Synergistic effect of chemo-photothermal therapy using PEGylated graphene oxide. Biomaterials 2011, 32:8555-8561.
27. Zhang L., Xia J., Zhao Q., Liu L., Zhang Z. Functional graphene oxide as a nanocarrier for controlled loading and targeted delivery of mixed anticancer drugs. Small 2010, 6:537-544.
28. Sun X., Liu Z., Welsher K., Robinson J.T., Goodwin A., Zaric S., Dai H. Nano-graphene oxide for cellular imaging and drug delivery. Nano Res. 2008, 1:203-212.
29. Markovic Z.M., Harhaji-Trajkovic L.M., Todorovic-Markovic B.M., Kepic D.P., Arsikin K.M., Jovanovic S.P., Pantovic A.C., Dramicanin M.D., Trajkovic V.S. In vitro comparison of the photothermal anticancer activity of graphene nanoparticles and carbon nanotubes. Biomaterials 2011, 32:1121-1129.
30. Xu Z., Zhu S., Wang M., Li Y., Shi P., Huang X. Delivery of paclitaxel using PEGylated graphene oxide as a nanocarrier. ACS Appl. Mater. Interfaces 2015, 7:1355-1363.
31. Zhao X., Yang L., Li X., Jia X., Liu L., Zeng J., Guo J., Liu P. Functionalized graphene oxide nanoparticles for cancer cell-specific delivery of antitumor drug. Bioconjug. Chem. 2015, 26:128-136.
32. Song E., Han W., Li C., Cheng D., Li L., Liu L., Zhu G., Song Y., Tan W. Hyaluronic acid-decorated graphene oxide nanohybrids as nanocarriers for targeted and pH-responsive anticancer drug delivery. ACS Appl. Mater. Interfaces 2014, 6:11882-11890.
33. Sanchez V.C., Jachak A., Hurt R.H., Kane A.B. Biological interactions of graphene-family nanomaterials: an interdisciplinary review. Chem. Res. Toxicol. 2012, 25:15-34.
34. Munoz M., Garcia-Erce J.A., Remacha A.F. Disorders of iron metabolism. Part II: iron deficiency and iron overload. J. Clin. Pathol. 2011, 64:287-296.
35. Terman A., Kurz T. Lysosomal iron, iron chelation, and cell death. Antioxid. Redox Signal 2013, 18:888-898.
36. Zhou A., Wei Y., Wu B., Chen Q., Xing D. Pyropheophorbide A and c(RGDyK) comodified chitosan-wrapped upconversion nanoparticle for targeted near-infrared photodynamic therapy. Mol. Pharm. 2012, 9:1580-1589.
37. Yang K., Zhang S., Zhang G., Sun X., Lee S.T., Liu Z. Graphene in mice: ultrahigh in vivo tumor uptake and efficient photothermal therapy. Nano Lett. 2010, 10:3318-3323.
38. Steere A.N., Byrne S.L., Chasteen N.D., Mason A.B. Kinetics of iron release from transferrin bound to the transferrin receptor at endosomal pH. Biochim. Biophys. Acta 2012, 1820:326-333.
39. Ma Q., Nakane Y., Mori Y., Hasegawa M., Yoshioka Y., Watanabe T.M., Gonda K., Ohuchi N., Jin T. Multilayered, core/shell nanoprobes based on magnetic ferric oxide particles and quantum dots for multimodality imaging of breast cancer tumors. Biomaterials 2012, 33:8486-8494.
40. Zhao P., Wang H., Yu M., Liao Z., Wang X., Zhang F., Ji W., Wu B., Han J., Zhang H., Chang J., Niu R. Paclitaxel loaded folic acid targeted nanoparticles of mixed lipid-shell and polymer-core: in vitro and in vivo evaluation. Eur. J. Pharm. Biopharm. 2012, 81:248-256.
41. Tsuji T., Yoshitomi H., Usukura J. Endocytic mechanism of transferrin-conjugated nanoparticles and the effects of their size and ligand number on the efficiency of drug delivery. Microsc. (Oxf) 2013, 62:341-352.
42. Dautry-Varsat A., Ciechanover A., Lodish H.F. pH and the recycling of transferrin during receptor-mediated endocytosis. Proc. Natl. Acad. Sci. U. S. A. 1983, 80:2258-2262.
43. Cirman T., Oresic K., Mazovec G.D., Turk V., Reed J.C., Myers R.M., Salvesen G.S., Turk B. Selective disruption of lysosomes in HeLa cells triggers apoptosis mediated by cleavage of Bid by multiple papain-like lysosomal cathepsins. J. Biol. Chem. 2004, 279:3578-3587.
44. Saunders D., Khemawoot P., Vanachayangkul P., Siripokasupkul R., Bethell D., Tyner S., Se Y., Rutvisuttinunt W., Sriwichai S., Chanthap L., Lin J., Timmermans A., Socheat D., Ringwald P., Noedl H., Smith B., Fukuda M., Teja-Isavadharm P. Pharmacokinetics and pharmacodynamics of oral artesunate monotherapy in patients with uncomplicated Plasmodium falciparum malaria in western Cambodia. Antimicrob. Agents Chemother. 2012, 56:5484-5493.
45. Liu Z., Cai W., He L., Nakayama N., Chen K., Sun X., Chen X., Dai H. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat. Nanotechnol. 2007, 2:47-52.
46. Liu Z., Davis C., Cai W., He L., Chen X., Dai H. Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:1410-1415.